Diamyd Medical (Nasdaq Stockholm First North Ticker: DMYD B) informs that immunological results from DIABGAD, one of five ongoing studies with the diabetes vaccine Diamyd®, will be presented at an international diabetes congress (IDS) held in Munich on April 12 to 16, 2015. Immunological findings from a study with Diamyd®, DIABGAD, will be presented by Professor Johnny Ludvigsson at an international diabetes meeting held in Munich on April 12-16, 2015. Preparations for the code break are ongoing and the code will be broken and the results analyzed shortly before the presentation. In the study, which is one of five ongoing studies with Diamyd®, Diamyd® plus vitamin D and ibuprofen is tested in order to strengthen the 16 percent (p = 0.10) average effect Diamyd®, as monotherapy, demonstrated compared to placebo in a European Phase III study. Among the speakers at the congress are several members of Diamyd Medical's Scientific Advisory Board; Professors Mark Atkinson, Åke Lernmark, Bart Roep and David Leslie. In addition, Anders Essen-Möller from Diamyd Medical is invited to give his views on the development of a diabetes vaccine from an industrial perspective. To be noted is that Craig Beam, Professor of Biostatistics, Kalamazoo, US, is invited to discuss the Bayesian statistical methods with which he recently reanalyzed results from three studies with the diabetes vaccine Diamyd® comprising more than 500 type 1 diabetes patients. The conclusion of the analysis of the European Phase III study is that the diabetes vaccine Diamyd® is effective with a probability of 97%. Prominent diabetes researchers who are co -authors to Craig Beam’s analysis results for Diamyd® include Jerry Palmer, Diane Wherrett, Kevin Herold, Johnny Ludvigsson, Colleen MacCallum and researchers within the Type 1 Diabetes TrialNet Study Group. The immunological results to be presented are from 6 months after the patients were enrolled in the study. The total number of patients is 64, divided into four groups: a) Diamyd® in combination with ibuprofen and vitamin D, b) Diamyd® in combination with vitamin D, c) Diamyd® in double dose in combination with vitamin D; d) Placebo (inactive substance). “We hope that the six-month results will show that this autoimmune disease is now modulated in the right direction,” says Anders Essen-Möller, President and CEO of Diamyd Medical. “If so, we have good hope that this, at 15 months, will provide a long-term positive effect on metabolic parameters such as the own ability to produce insulin. The last patient will perform the 15 month visit in September 2015 and metabolic results from the study are planned to be presented by the end of this year.” About the diabetes vaccine Diamyd® Type 1 diabetes is a devastating disease which requires daily treatment with insulin to sustain life. The importance of finding a cure cannot be underestimated. Diamyd® is considered to be the world’s furthest developed Antigen Based Therapy (ABT) for treating the disease. Diamyd® has been used in clinical studies with more than 1,000 patients and has shown a good safety profile. In a European Phase III study Diamyd® showed good clinical effect in several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving endogenous insulin secretion. To enhance the overall effect, combination treatments with Diamyd® and other approved agents are being pursued. Diamyd® is easy to administer in any clinical setting. The potential annual market is estimated to several billion dollars. About Diamyd Medical Diamyd Medical is dedicated to working toward a cure for type 1 diabetes. The Company’s projects include development of combination regimens with the GAD -based diabetes vaccine Diamyd® for arresting the destruction of insulin -producing beta cells. The Company exclusively licenses UCLA-rights to GAD65, the active ingredient in the vaccine, for which the last patent expires in 2032. Additionally, the Company exclusively licenses UCLA patents for using GABA for the treatment of diabetes and other inflammation-related conditions. Diamyd Medical is one of the major shareholders in the stem cell company Cellaviva AB, which is establishing a Swedish commercial bank for private family saving of stem cells in umbilical cord blood and other sources of stem cells. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example, to restore beta cell mass in diabetes patients where autoimmunity has been arrested. Remium Nordic AB is the Company’s Certified Adviser. For further information, please contact: Anders Essen-Möller, President and CEO Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.
Immunological results from a study with Diamyd® will be
Top 10 Most Recent News Articles
Pepsi Faces Georgia Labor Pressure Ahead of Strike
A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...
Continue Reading
Fluence Investors Face a November 27 Litigation Clock
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus
A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....
Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain
Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...
Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
DISA Backs Nursing Education With OADN Foundation Push
A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...
Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data
Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...
Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office
Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...
Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire
A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...
Continue ReadingTop 5 Most Recently Viewed Articles
GLS and APES Join Forces in Semiconductor Packaging Venture
Opportunities and Risks in the Semiconductor Landscape Alright, let’s get into it. Great Lakes Semiconductor (GLS) teaming up with Advanced Printed Electronic Solutions (APES) sounds like a match made in tech heaven, but it also raises some eyebrows. Personally, I’ve been around the block enough to recognize that in this line of business, one misstep can feel like a...
Continue Reading
Renaissance Acquires Ansel Health, Enhancing Insurance Solutions
Renaissance's Strategic Acquisition of Ansel Health Renaissance Life & Health Insurance Company of America has recently acquired Ansel Health, a transformative technology company in the supplemental health insurance domain. Innovating Health Insurance Solutions This acquisition not only enhances Renaissance's service portfolio but also promises to lead the way in...
Continue Reading
High-Trend International Group's Revenue Soars with New Strategies
High-Trend International Group Sees Massive Revenue Growth High-Trend International Group (NASDAQ: HTCO), a prominent name in ocean technology, has shared its impressive financial results. The Company has achieved a remarkable surge in revenue, marking a pivotal moment in its business journey. Understanding the latest financial summary showcases how effective new...
Continue Reading
Innovative Device Enhances At-Home Medical Exam Experience
Revolutionizing Self-Exams with Innovative Design In today's fast-paced world, health awareness is more crucial than ever. Individuals often seek ways to monitor their health conveniently from the comfort of their home. Recognizing this need, an inventive mind has developed a unique device aimed at simplifying personal health examinations. The MEDICAL EXAM WAIST BAND...
Continue Reading
Navitas Unveils Groundbreaking Power Supply for AI Data Centers
Navitas Semiconductor Makes Waves in AI Power Supply Solutions Navitas Semiconductor, a trailblazer in power semiconductor technology, is set to impress at the upcoming power electronics conference in China. Their latest innovation, the world's first 8.5 kW AI data center power supply, integrates leading-edge gallium nitride (GaN) and silicon carbide (SiC) technologies....
Continue Reading